Investor Relations

About Company

ImmunityBio, Inc. and NantKwest, Inc. merged on March 9, 2021 to create a leading late-stage, cell therapy and immunotherapy company focused on oncology and infectious diseases. The combined company is called ImmunityBio, Inc. (NASDAQ: IBRX).

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients

Jun 10, 2021

ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa

May 25, 2021

ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference

May 24, 2021

ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021

May 20, 2021

Events

Contact Information

IR Contact

ImmunityBio Investor Relations

Phone: 1-844-696-5235, Option 5
Email

Transfer Agent & Stockholder Services

American Stock Transfer & Trust Company, LLC

AST Shareholder Services Call Center
Toll Free: 800.937.5449
Local & International: 718-921-8124
Hours: 8 a.m. – 8 p.m. ET Monday-Friday

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
Email
Website